Study in Patients With Asthma

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00215358

Enrollment

Registered

2005-09-22

Start date

2002-07-31

Completion date

2005-12-31

Last updated

2010-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

Asthma, Formoterol, Fumarate, Foradil

Brief summary

The purpose of this study is to determine which dose of the investigational drug is safest and most effective compared to the control drug.

Interventions

DRUGFormoterol Fumarate

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

12 Years to 70 Years

Healthy volunteers

Inclusion criteria

-Require regular use of an inhaled Beta-2-selective adrenergic agent

Exclusion criteria

* Active acute or chronic disorders of the respiratory system within one month prior to screening * Smoking history within the past 12 months or greater than a lifetime 10 pack-year smoking history * Recent surgical interventions such as lung lobectomy or resection (\< one year), or cardiothoracic interventions * Life-threatening systemic and debilitating diseases.

Design outcomes

Primary

Measure	Time frame
Measure of lung function.	—

Secondary

Measure	Time frame
Change in lung function, vital signs, physical examinations, clinical laboratory assessments, and adverse event reporting.	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026